Cogent Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$333.4 | -$275.9 | -$208.1 | -$147.8 | -$75.6 |
| Net income | -$328.9 | -$255.9 | -$192.4 | -$140.2 | -$72.3 |
| Balance Sheet | |||||
| Total debt | $230.0 | — | — | — | — |
| Cash Flow Statement | |||||
| Free cash flow | -$266.0 | -$208.4 | -$156.4 | -$125.5 | -$60.5 |
Shares outstanding 170.9M · Free float 82.8%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.